多西他賽與奈達鉑聯合治療晚期非小細胞肺癌的效果分析

王翕田

【摘要】 目的：研究多西他賽與奈達鉑聯合治療晚期非小細胞肺癌的作用。方法：選擇2015年1月-2017年12月筆者所在醫院收治的130例晚期非小細胞肺癌患者作為研究對象，隨機均分為對照組與觀察組，每組65例。兩組均根據自身情況實施抗過敏治療及止吐治療，對照組于此基礎上給予多西他賽治療，觀察組于多西他賽治療基礎上聯合奈達鉑治療。比較兩組平均生存時間、治療效果、并發癥發生情況。結果：觀察組治療總有效率為95.38%，高于對照組的72.31%，且觀察組生存平均時間長于對照組，觀察組并發癥發生率為3.08%，低于對照組的29.23%，兩組差異均有統計學意義（P<0.05）。結論：多西他賽聯合奈達鉑是一種科學有效的治療方案，對晚期非小細胞肺癌控制病情、延長壽命具有重要意義。

【關鍵詞】 晚期非小細胞肺癌; 臨床效果; 多西他賽; 奈達鉑

doi：10.14033/j.cnki.cfmr.2019.19.054 文獻標識碼 B 文章編號 1674-6805（2019）19-0-02

Efficacy of Docetaxel Combined with Nedaplatin in Treatment of Advanced Non-small Cell Lung Cancer/WANG Xitian.//Chinese and Foreign Medical Research，2019，17（19）：-121

【Abstract】 Objective：To study the effect of Docetaxel combined with Nedaplatin in the treatment of advanced non-small cell lung cancer.Method：A total of 130 patients with advanced non-small cell lung cancer admitted to the hospital from January 2015 to December 2017 were randomly divided into control group and observation group，with 65 cases in each group.Both groups were treated with anti-allergic treatment and antiemetic treatment according to their own conditions.The control group was given Docetaxel on this basis，and the observation group was treated with Nedaplatin on the basis of docetaxel treatment.The average survival time，treatment effect，and complications of the two groups were compared.Result：After treatment，the effective rate of the observation group was 95.38%，which was much higher than 72.31% of the control group.The average survival time of the observation group was longer than that of the control group.The incidence of complications in the observation group was 3.08%，which was lower than 29.23% of the control group.There were significant differences between the two groups（P<0.05）.Conclusion：Docetaxel combined with Nedaplatin is a scientific and effective treatment for advanced non-small cell lung cancer.It is of great significance to control the disease and prolong the life span of advanced non-small cell lung cancer.

【Key words】 Advanced non-small cell lung cancer; Clinical effect; Docetaxel; Nedaplatin

First-authors address：Chuxiong Peoples Hospital，Chuxiong 675000，China

新時期，隨著人們生活水平的不斷提高，生活方式及習慣也在不斷發生變化，各大醫院對惡性腫瘤的報道逐年增多。權威數據顯示，每年肺癌的發病率在所有惡性腫瘤中占50%以上[1-2]，其中發病人群以男性居多，大部分患者均表現為非小細胞肺癌。此病發病較隱匿，在發病初期很難被發現，一旦確診即為晚期。晚期非小細胞肺癌患者已經失去手術機會[3-4]，所以臨床多采取化療方案控制病灶，提高生活質量。筆者為分析多西他賽與奈達鉑聯合治療價值，報道如下。

1 資料與方法

1.1 一般資料

選取2015年1月-2017年12月筆者所在醫院收治的130例晚期非小細胞肺癌患者為研究對象。納入晚期非小細胞肺癌患者，生存期均大于半年，白細胞數目均大于3.9×109/L[5-6]。